This puts new blood and a pipeline of needed products in the revenue stream. This could be a blockbuster for BMY to move it up and out of its trading range.
SHort term, the stock may go down because of the acquisition. Long term also there are some risks as some of drugs being developed may not be approved. However good news for the being acquired.